Cardiac Arrest Treatment Market By Product Type (Automated & Professional Defibrillators, CPR & Mechanical Compression Devices, Emergency Drugs, Airway & Vascular Access Products, Patient Monitoring & Temperature Management Systems, Wearable Cardioverter-Defibrillators, Implantable Cardioverter-Defibrillators); By Care Pathway (Basic Life Support, Advanced Cardiovascular Life Support, Diagnostic Evaluation, Post-Cardiac Arrest Critical Care, Secondary Prevention); By Diagnostic Assessment (ECG & Rhythm Monitoring, Blood Testing, Echocardiography, X-Ray, CT & MRI, Nuclear Cardiac Imaging, Cardiac Catheterisation, Electrophysiology & Genetic Testing); By End User (Hospitals & Cardiac Centres, EMS & Ambulance Services, Public-Access Facilities, Schools & Workplaces, Ambulatory Centres, Home & Community Response Networks); By Geography, Segment Revenue Estimation and Forecast, 2026–2032

Cardiac Arrest Treatment Market: Defibrillator Access, Emergency Readiness, and Post-Arrest Care Shape Commercial Demand

The Global Cardiac Arrest Treatment Market is projected to grow from USD 5.23 billion in 2025 to USD 7.86 billion by 2032, expanding at a CAGR of 6.0%, according to Strategic Market Research.

 

The market covers the equipment, medicines, procedures, diagnostic tests, and emergency-response systems used from collapse through hospital recovery and prevention of another arrest. It includes automated external defibrillators, professional monitor-defibrillators, CPR and mechanical compression equipment, emergency medicines, vascular-access and airway products, patient monitors, temperature-management systems, diagnostic imaging, intensive-care services, wearable defibrillators, and implantable cardioverter-defibrillators.

 

This is primarily a device- and service-led market. High-quality CPR and early defibrillation have the greatest immediate effect on survival, while medicines support circulation or address specific rhythms and reversible causes. Commercial demand is therefore concentrated in AED deployment, ambulance and hospital replacement cycles, electrodes, batteries, maintenance, training, connectivity, diagnostic testing, post-resuscitation monitoring, and secondary-prevention devices.

 

Cardiac Arrest Burden Keeps Emergency Investment High

The United States records more than 356,000 out-of-hospital cardiac arrests annually, while nearly 300,000 additional arrests occur inside hospitals. Together, these settings create an emergency-treatment pool exceeding 650,000 episodes per year. The two settings produce different procurement requirements: community and EMS systems prioritise rapid access, portability, CPR guidance, and dispatch integration, while hospitals require monitor-defibrillators, code-response systems, airway products, vascular access, continuous monitoring, temperature control, and intensive-care support. 

 The 2025 CARES registry recorded 140,427 non-traumatic, EMS-treated arrests across a covered population exceeding 189 million people. Median response time was 7.6 minutes. Overall survival to discharge was 10.5%, increasing to 16.1% when the arrest was witnessed by a bystander and falling to 4.3% when unwitnessed. Survival reached 37% in witnessed, shockable arrests under favourable Utstein conditions. Bystanders performed CPR in 42.5% of cases but applied an AED in only 13.9% of public-location arrests. 

 The registry also clarifies how the treatment population converts into downstream revenue. Of 140,427 treated events, 35,588 patients survived to hospital admission and 14,768 survived to discharge. Only 11,608 were discharged with good or moderate cerebral performance. The market must therefore distinguish between the large resuscitation population and the much smaller group progressing into intensive care, coronary procedures, neurological assessment, rehabilitation, and long-term rhythm protection.

Around 71.4% of CARES arrests occurred in residences, 17.5% in public places, and 11.1% in nursing homes. Approximately 84% of adult non-traumatic events had a presumed cardiac cause, followed by respiratory causes at 9.7% and overdose at 4.5%. The concentration of arrests inside homes limits the impact of public AED placement alone and supports residential responder networks, dispatcher-assisted CPR, connected community alerts, wearable defibrillators, and selected home AED programmes.

 

Regional Registries Show Uneven Survival and AED Use

Around 115,000 out-of-hospital cardiac arrests are reported to UK ambulance services each year, with resuscitation attempted in approximately 43,000 cases. Between 70% and 80% occur at home. Public AED use remains below 11% across England, Northern Ireland, Scotland, and Wales, while 30-day survival generally remains below 10%. The UK also recorded 12,755 in-hospital cardiac arrests during 2023–2024, with 25.8% of patients surviving to discharge. 

Canada experiences an estimated 60,000 out-of-hospital cardiac arrests annually, or roughly one every nine minutes, with survival near one in ten. Heart & Stroke and its partners have placed more than 15,000 AEDs in Canadian communities since 2010, while more than 9,000 instructors support CPR and AED training. This demonstrates that market value extends beyond hardware into education, certification, medical oversight, consumables, and programme management. 

Australia and New Zealand recorded 38,646 out-of-hospital arrests in 2022. Bystanders applied an AED in only 1.9% of cases, and survival was 11.1%, rising to around 30% in witnessed shockable events. Japan has one of the world’s largest public AED networks, with an estimated installed base near 690,000 units. However, citizen shocks remain uncommon relative to the number of arrests, keeping future investment focused on device mapping, public alerts, dispatcher integration, education, and faster retrieval.

 

Defibrillation and CPR Form the Commercial Core

The immediate treatment pathway begins with recognition, an emergency call, CPR, and AED use. The American Heart Association recommends chest compressions at 100–120 per minute and using an AED as soon as it becomes available. Immediate CPR can double or triple survival probability, while combined CPR and early defibrillation can produce substantially higher survival in witnessed shockable arrests. 

This creates demand beyond the defibrillator itself. A complete readiness programme requires cabinets, signage, adult and paediatric pads, batteries, training devices, CPR mannequins, inspection records, medical oversight, software updates, device registration, emergency plans, and replacement after use or expiry. The American Heart Association trains more than 22 million people globally in CPR each year, illustrating the size of the training and certification layer surrounding resuscitation equipment.

Emergency medicines remain protocol-driven. Epinephrine is used during shockable and non-shockable rhythms, while amiodarone or lidocaine may be used when ventricular fibrillation or pulseless ventricular tachycardia persists despite defibrillation. Magnesium, calcium, sodium bicarbonate, and fibrinolytics are reserved for selected arrhythmias, electrolyte abnormalities, toxicological causes, or suspected pulmonary embolism. Drug demand is stable but predominantly generic, driven by crash-cart stocking, ambulance inventories, prefilled syringes, expiry replacement, emergency packaging, and supply reliability.

 

Diagnostic Testing Expands Revenue After Circulation Returns

A patient who regains circulation enters a second commercial pathway focused on identifying the cause of the arrest and measuring cardiac, metabolic, and neurological injury. Mayo Clinic identifies blood testing, electrocardiography, echocardiography, ejection-fraction measurement, chest X-ray, nuclear imaging, and cardiac catheterisation among the principal investigations after sudden cardiac arrest. 

 The existing diagnostic infrastructure supporting this pathway is substantial. More than 300 million resting 12-lead ECG tests are estimated to be performed globally each year across hospitals, clinics, and ambulatory-care settings, while healthcare providers conduct approximately 25 million standard ECG procedures annually in the United States. More than 72 million long-term ECG tests, including Holter and extended rhythm-monitoring examinations, are also estimated to be conducted worldwide each year. These volumes support demand for conventional ECG systems, Holter monitors, wearable patches, electrodes, cables, recording software, interpretation services, and connected rhythm-analysis platforms.

Blood tests measure cardiac injury markers and assess potassium, magnesium, hormones, and other abnormalities affecting heart function. ECG can identify arrhythmias or ischaemic changes. Echocardiography evaluates heart muscle, valves, blood flow, and pumping capacity. An ejection fraction below 40% is associated with increased sudden-arrest risk and may influence decisions concerning wearable or implantable defibrillator therapy. Industry estimates indicate that approximately 20 million echocardiograms are performed in the United States annually, providing a large installed clinical base for ultrasound systems, transducers, contrast agents, analysis software, maintenance, and image-management services.

Chest radiography may help clinicians evaluate lung complications, cardiac enlargement, aspiration, rib injuries, vascular-device positioning, or other conditions following resuscitation. Approximately 2 billion chest X-rays are estimated to be performed globally each year, including nearly 70 million annually in the United States, making chest radiography one of the most frequently used medical imaging procedures. Although only a fraction is directly linked to cardiac arrest, this installed testing volume supports rapid access to digital radiography systems in emergency departments and intensive-care units.

Cardiac catheterisation can identify obstructed coronary arteries and convert immediately into angioplasty or stent placement when a treatable lesion is found. The AHA also identifies exercise testing, electrophysiology studies, advanced imaging, ambulatory monitoring, and genetic testing as possible parts of the post-arrest work-up. Genetic evaluation may extend to relatives when an inherited arrhythmia syndrome or cardiomyopathy is suspected, widening the addressable market into family screening and preventive cardiology.

Nuclear cardiac imaging can be used in selected patients to assess myocardial perfusion, ventricular function, tissue viability, or underlying coronary disease. An estimated 40 million to 50 million nuclear medicine procedures are performed worldwide each year. The United States accounts for approximately 13.5 million to 20 million nuclear imaging and medicine procedures annually, representing roughly one-third of global activity. Only a selected proportion relates to post-arrest cardiac assessment, but the wider procedure base supports demand for gamma cameras, SPECT and PET systems, radiopharmaceuticals, cardiac imaging software, and specialist interpretation.

Post-arrest neurological assessment may include CT, MRI, EEG, somatosensory evoked potentials, biomarkers, pupillometry, and repeated clinical examination. These tests create revenue across emergency medicine, cardiology, intensive care, neurology, laboratory diagnostics, imaging, and hospital informatics. Suppliers that connect these results within a unified patient record can capture more of the treatment pathway than companies selling isolated resuscitation devices.

 

Hospital Care Broadens Revenue Beyond Resuscitation

Patients who regain circulation may require mechanical ventilation, oxygen therapy, capnography, arterial blood-gas testing, vasopressors, infusion pumps, invasive pressure monitoring, continuous ECG, neurological observation, imaging, coronary angiography, and intensive-care admission. Current AHA guidance recommends avoiding hypotension and maintaining mean arterial pressure of at least 65 mm Hg, supporting sustained use of bedside monitors, vascular-access systems, infusion technology, and critical-care disposables. 

Protocolised temperature control is recommended for adults who remain unresponsive after circulation returns. AHA guidance recommends maintaining a temperature between 32°C and 37.5°C for at least 36 hours. Surface and endovascular systems create recurring demand for consoles, cooling pads, blankets, probes, sensors, intravascular catheters, and disposables. Routine rapid infusion of cold intravenous fluid is not recommended, shifting purchasing toward controlled temperature-management platforms.

Coronary angiography is important when an acute coronary blockage may have caused the arrest, particularly in patients with persistent ST-segment elevation, shock, recurrent ventricular arrhythmias, or continuing ischaemia. PCI-related revenue should not, however, be applied to every arrest patient. A large proportion die before reaching hospital, and not every survivor has an acute coronary lesion requiring intervention. CABG, cardiac ablation, ECMO, and temporary mechanical circulatory support are also high-value but selective treatments that should be modelled only within clinically eligible groups.

 

Long-Term Defibrillator Care Creates Recurring Revenue

Survivors who remain at risk of ventricular fibrillation or ventricular tachycardia may receive an implantable cardioverter-defibrillator during the hospital stay or shortly after discharge. Others use a wearable cardioverter-defibrillator while clinicians determine whether ventricular function will recover or whether permanent implantation is required. This secondary-prevention pathway generates long-term revenue through device implantation, leads, generators, programming, remote monitoring, clinical follow-up, software, replacement procedures, and management of alerts.

ZOLL states that its LifeVest wearable cardioverter-defibrillator has been used by more than one million patients and supported by peer-reviewed evidence covering more than 140,000 patients. The company reports first-shock success above 97% across clinical trials and real-world analyses. These figures demonstrate the scale of the temporary-protection segment between hospital discharge, recovery of ventricular function, and permanent ICD selection. 

Medtronic’s Aurora extravascular ICD offers defibrillation, antitachycardia pacing, and backup pacing while positioning the lead beneath the breastbone but outside the heart and veins. In the pivotal study supporting FDA approval, the system achieved 98.7% defibrillation success at implantation, while 92.6% of patients were free from major system- or procedure-related complications at six months. 

Boston Scientific’s UNTOUCHED study evaluated 1,111 patients implanted with the EMBLEM subcutaneous ICD. The system achieved a 95.9% inappropriate-shock-free rate at 18 months, while patients using the SMART Pass sensing filter achieved a 97.6% rate at one year. At the time of the results, more than 75,000 patients had received the company’s S-ICD worldwide. Clinical evidence concerning sensing, shock accuracy, infection exposure, lead placement, and complication avoidance now materially influences electrophysiology procurement. 

 

Schools, Workplaces, and Registries Expand AED Demand

England delivered 20,376 defibrillators to 17,862 state-funded schools through approximately £19 million in public funding. The United States had 99,297 public schools and around 49.4 million students in 2023–2024, creating a large addressable network for AEDs, paediatric accessories, training, cabinets, inspection, and replacement. 

The AHA estimates that around 10,000 cardiac arrests occur at U.S. workplaces annually, yet only about half of employees can locate an AED. Managed workplace programmes increasingly combine devices with cabinets, monitoring, financing, training, emergency plans, and technical support. Philips’ partnership with Securitas and Medic Assist reflects this move from standalone equipment toward managed safety services.

The UK’s Circuit registered more than 108,000 AEDs by 2025, while PulsePoint’s National Emergency AED Registry connected more than 200,000 devices to emergency responders by December 2025. Registry integration allows dispatchers to identify nearby devices and supports community analysis of coverage gaps. Avive’s USD 56.5 million funding round in 2024 and NASPO ValuePoint contract for 2024–2029 also demonstrate investor and government interest in connected public-access networks.

 

Automatic Testing and Connectivity Reshape Procurement

AED buyers increasingly require evidence that a device, battery, pads, and communications system were ready when needed. Stryker’s LIFEPAK CR2 performs automatic self-tests daily, weekly, monthly, and whenever the unit is switched on. Connected devices report to the LIFELINKcentral platform, which can notify programme managers when an AED detects a problem or fails to check in.

Philips’ HeartStart FRx conducts daily, weekly, and monthly tests covering pad readiness, circuits, functionality, and calibration. Its battery can provide up to four years of standby life under specified conditions. ZOLL’s AED 3 checks battery capacity, electrode connection and expiry, ECG circuitry, charging and discharging functions, software, audio systems, and CPR-sensor circuitry. Its monthly assessment includes a full-energy 200-joule test.

Defibtech’s Lifeline VIEW performs automatic circuitry tests daily, weekly, monthly, and quarterly and checks preconnected pad presence every day. These capabilities make self-testing coverage, battery longevity, pad expiry, remote alerts, and fleet dashboards measurable procurement variables.

Automatic testing does not eliminate maintenance. Pads expire, batteries degrade, devices can be moved or damaged, and recalls may require serial-number-level intervention. A 2024 FDA-listed correction affected 183,248 Stryker HeartSine devices, while a separate Defibtech action covered 22,294 paediatric pad units. Such events increase the value of authorised distribution, registration, recall tracking, expiry alerts, and rapid field correction.

Professional defibrillator competition is also expanding beyond shock delivery. Stryker’s LIFEPAK 35 monitor-defibrillator combines defibrillation with ECG, patient monitoring, CPR analysis, clinical decision support, and connected data capabilities. Hospitals and EMS organisations increasingly evaluate event-data transfer, electronic-record integration, capnography, CPR feedback, paediatric capability, cybersecurity, software updates, battery interchangeability, consumable costs, and service coverage.

 

Cardiac Arrest Treatment Market Outlook

Growth through 2032 will be led by public-access AED deployment, replacement of ageing professional defibrillators, school and workplace readiness programmes, connected residential response, recurring electrodes and batteries, remote monitoring, registry integration, maintenance, training, and post-resuscitation care.

Diagnostic testing will contribute a growing share of treatment revenue as survivors undergo ECG, echocardiography, laboratory testing, CT, MRI, EEG, catheterisation, electrophysiology studies, and genetic evaluation. Temperature management, neurological monitoring, ventilation, haemodynamic support, wearable defibrillation, and implantable rhythm devices expand revenue beyond the initial emergency event.

The market still faces low bystander AED use, uneven geographic access, fragmented procurement, generic-drug pricing, device-maintenance failures, and the concentration of arrests inside private homes. Competitive advantage is shifting away from standalone hardware toward readiness systems combining approved devices, consumables, registration, remote testing, dispatch integration, financing, training, and regulatory tracking.

A credible market model should not count every diagnostic test, PCI, CABG procedure, ECMO episode, wearable defibrillator, or ICD implant against the full arrest population. More than 650,000 annual U.S. arrests represent the broad emergency-treatment pool, while only a fraction survives and progresses into higher-value downstream care. Separating the resuscitation population, hospital-admission population, discharge-survivor population, and secondary-prevention population prevents forecast inflation while capturing revenue generated across emergency response, hospital recovery, and recurrence prevention.

 

Cardiac Arrest Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 5.23 Billion
Revenue Forecast in 2032	USD 7.86 Billion
Overall Growth Rate	CAGR of 6.0% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026– 2032)
Segmentation	By Product Type, By Care Pathway, By Diagnostic Assessment, By End User, By Geography
By Product Type	Automated & Professional Defibrillators, CPR & Mechanical Compression Devices, Emergency Drugs, Airway & Vascular Access Products, Patient Monitoring & Temperature Management Systems, Wearable Cardioverter-Defibrillators, Implantable Cardioverter-Defibrillators
By Care Pathway	Basic Life Support, Advanced Cardiovascular Life Support, Diagnostic Evaluation, Post-Cardiac Arrest Critical Care, Secondary Prevention
By Diagnostic Assessment	ECG & Rhythm Monitoring, Blood Testing, Echocardiography, X-Ray, CT & MRI, Nuclear Cardiac Imaging, Cardiac Catheterisation, Electrophysiology & Genetic Testing
By End User	Hospitals & Cardiac Centres, EMS & Ambulance Services, Public-Access Facilities, Schools & Workplaces, Ambulatory Centres, Home & Community Response Networks
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising cardiac arrest incidence, expanding public-access AED programmes, increasing emergency response readiness, growing adoption of connected defibrillation systems, demand for post-arrest critical care technologies, and rising focus on secondary prevention through implantable and wearable defibrillators
Customization Option	Available upon request